Suchergebnisse - "Sgroi, D"

PubPharm (60)

1

Telemedicine : a Proxemics tool of Primary Care?

enthalten in: Igiene e sanita pubblica | 2020

von Amato, S. | Sgroi, D. | Di Giovanni, C. | +3

2

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2019

von Bartlett, J. | Sgroi, D. | Treuner, K. | +8

CommentIn: Ann Oncol. 2019 Nov 1;30(11):1677-1681. - PMID 31613310

3

Abstract P1-06-03: Serial evolution of hormone receptor status and mutational profile among patients with metastatic breast cancer

enthalten in: Cancer research | 2017

von Henderson, L. | Brachtel, E. | Fitzgerald, D. | +9

4

Cross Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in women with hormone receptor positive lymph-node negative early stage breast cancer

enthalten in: Clinical cancer research | 2016

von Sestak, I. | Zhang, Y. | Schroeder, B. | +4

5

Biomarkers for Early-Stage Breast Cancer: Clinical Utility for Extended Adjuvant Treatment Decisions

enthalten in: Journal of clinical oncology / Englische Ausgabe | 2016

von Sgroi, D. | Brufsky, A.

6

Alternative polyadenylation in triple-negative breast tumors allows NRAS and c-JUN to bypass PUMILIO post-transcriptional regulation

enthalten in: Cancer research | 2016

von Miles, W. | Lembo, A. | Volorio, A. | +5

7

Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer

enthalten in: Clinical cancer research | 2016

von Sestak, I. | Zhang, Y. | Schroeder, B. | +4

8

Nodes-and-connections RNAi knockdown screening : identification of a signaling molecule network involved in fulvestrant action and breast cancer prognosis

enthalten in: Oncogenesis | 2015

von Miyoshi, N. | Wittner, B. | Shioda, K. | +6

9

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2013

von Weiner, M. | Skoog, L. | Fornander, T. | +3

10

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer

enthalten in: Annals of oncology | 2013

von Weiner, M. | Skoog, L. | Fornander, T. | +3

1
2
3
4
5
6
Nächster »
[6]